MCAC Likely Will Assess Potential Postmarket Surveillance Of LVADs
This article was originally published in The Gray Sheet
Executive Summary
CMS expects the Medicare Coverage Advisory Committee to consider recommending postmarket registries of left-ventricular assist devices as a condition of national coverage
You may also be interested in...
Who Gets LVAD? Medicare Panel Considers Candidacy, Classification Scheme
Restricting Medicare coverage of permanent left-ventricular assist devices to patients formally evaluated by Medicare-approved heart transplant centers is among options to be reviewed by the Medicare Coverage Advisory Committee March 12
Who Gets LVAD? Medicare Panel Considers Candidacy, Classification Scheme
Restricting Medicare coverage of permanent left-ventricular assist devices to patients formally evaluated by Medicare-approved heart transplant centers is among options to be reviewed by the Medicare Coverage Advisory Committee March 12
LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains